China Isotope & Radiation Corporation (HKG:1763)

China Isotope & Radiation Revenue

China Isotope & Radiation had revenue of 2.99B CNY in the half year ending June 30, 2026, with 6.53% growth. This brings the company's total for the last twelve months to 7.31B, down -4.18% year-over-year. In the year 2025, China Isotope & Radiation had annual revenue of 7.19B, down -5.11%. That makes China Isotope & Radiation the 7,280th largest company in the world by revenue and 464th in Hong Kong.

• Revenue (ttm): 7.31B CNY
• Revenue Growth: -4.18%
• P/S Ratio: 0.46
• Revenue / Employee: 2.00M CNY
• Employees: 3,655
• Market Cap: 3.77B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Segment

Chart

• Nuclear Medicines 4.02B 55.4%
• Other Businesses 1.60B 22.1%
• Radioactive Sources and Application 835.65M 11.5%
• Nuclear Medical Equipment and Related Services 601.55M 8.3%
• Irradiation Application 191.30M 2.6%

Fiscal year ended Dec 31, 2025 See the full China Isotope & Radiation breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	7.19B	-387.10M	-5.11%
Dec 31, 2024	7.57B	939.76M	14.16%
Dec 31, 2023	6.63B	481.44M	7.82%
Dec 31, 2022	6.15B	1.01B	19.63%
Dec 31, 2021	5.14B	869.51M	20.34%

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 19, 2026

Data Sources Report a data error